Picking a fight with parasites! Trypanothione reductase (TR) is a validated drug target for the development of antileishmanial agents. A group of structurally diverse gold-containing compounds was evaluated in vitro for TR inhibition. A number of compounds exhibited potent activity and deserve further pharmacological evaluation
New ferrocenic 4-aminoquinoline urea compounds have been tested for inhibition of trypanothione redu...
High-throughput screening of 100,000 lead-like compounds led to the identification of nine novel che...
Leishmaniasis, Chagas disease, and sleeping sickness affect millions of people worldwide and lead to...
The drugs currently used to treat leishmaniasis have limitations concerning cost, efficacy and safet...
Trypanothione reductase (TR) is considered to be one of the best targets to find new drugs against L...
Trypanothione reductase (TR) is considered to be one of the best targets to find new drugs against L...
Trypanosomiasis and leishmaniasis are two debilitating disease groups caused by parasites of Trypano...
Trypanosomes and Leishmania, the causative agents of African sleeping sickness, Chagas disease, and ...
Auranofin is a gold(I)-containing drug in clinical use as an antiarthritic agent. Recent studies sho...
The protozoans Leishmania and Trypanosoma, belonging to the same Trypanosomatidae family, are the ca...
Trypanothione reductase, an essential component of the anti-oxidant defences of parasitic trypanosom...
Trypanothione reductase (TryR) is a key validated enzyme in the trypanothione-based redox metabolism...
In Leishmania the glutathione/glutathione reductase eukaryotic redox sys-tem is replaced by the uniq...
Herein we report a study aimed at discovering a new class of compounds that are able to inhibit Leis...
Herein we report a study aimed at discovering a new class of compounds that are able to inhibit Leis...
New ferrocenic 4-aminoquinoline urea compounds have been tested for inhibition of trypanothione redu...
High-throughput screening of 100,000 lead-like compounds led to the identification of nine novel che...
Leishmaniasis, Chagas disease, and sleeping sickness affect millions of people worldwide and lead to...
The drugs currently used to treat leishmaniasis have limitations concerning cost, efficacy and safet...
Trypanothione reductase (TR) is considered to be one of the best targets to find new drugs against L...
Trypanothione reductase (TR) is considered to be one of the best targets to find new drugs against L...
Trypanosomiasis and leishmaniasis are two debilitating disease groups caused by parasites of Trypano...
Trypanosomes and Leishmania, the causative agents of African sleeping sickness, Chagas disease, and ...
Auranofin is a gold(I)-containing drug in clinical use as an antiarthritic agent. Recent studies sho...
The protozoans Leishmania and Trypanosoma, belonging to the same Trypanosomatidae family, are the ca...
Trypanothione reductase, an essential component of the anti-oxidant defences of parasitic trypanosom...
Trypanothione reductase (TryR) is a key validated enzyme in the trypanothione-based redox metabolism...
In Leishmania the glutathione/glutathione reductase eukaryotic redox sys-tem is replaced by the uniq...
Herein we report a study aimed at discovering a new class of compounds that are able to inhibit Leis...
Herein we report a study aimed at discovering a new class of compounds that are able to inhibit Leis...
New ferrocenic 4-aminoquinoline urea compounds have been tested for inhibition of trypanothione redu...
High-throughput screening of 100,000 lead-like compounds led to the identification of nine novel che...
Leishmaniasis, Chagas disease, and sleeping sickness affect millions of people worldwide and lead to...